English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Objective:   To assess the effect of cardioselective b-blockers on pulmonary function in patients with chronic obstructive pulmonary disease (COPD).Methods:   The Embase and MEDLINE™ databases and the Cochrane Controlled Trials Register were searched comprehensively to identify all relevant clinical trials in humans published between January 1966 and May 2011. Randomized, blinded, placebo-controlled trials that studied the effects of cardioselective ß-blockers on the forced expiratory volume in 1 s (FEV1) and the responsiveness of the FEV1 to ß-agonist administration in patients with COPD were included in the analysis.Results:   Five studies were identified: four of these assessed both cardioselective and nonselective ß-blockers; one assessed only cardioselective ß-blockers. The FEV1 was shown to decrease by 0.14 l with nonselective ß-blockers and by 0.03 l with cardioselective ß-blockers. The responsive -ness of the FEV1 to ß-agonist administration decreased significantly by 13.42% after nonselective ß-blockers, but did not change significantly after cardioselective -blocker administration.Conclusion:   This meta-analysis suggests that the use of β-blockers, especially cardioselective β-blockers, should not be contraindicated in patients with COPD.

journal of international medical research

Use of Cardioselective ß-Blockers in Patients with Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized, Placebo-controlled, Blinded Trials